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Purpose: We aimed to study the radiation induced brachial plexopathy in patients with head and neck squamous
cell carcinoma (HNSCC) treated with Sequential Intensity Modulated Radiation Therapy (S-IMRT).
Methods and materials: This IRB approved study included 68 patients with HNSCC treated consecutively. Detailed
dose volume histogram data was generated for ipsilateral and contralateral brachial plexus (BP) volumes receiving a
specified dose (Vds) i.e. V50-V75 and dose in Gray covering specified percent of BP volume (Dvs) i.e. D5-D30 and
maximum point doses (Dmax). To assess BP injury all patients’ charts were reviewed in detail for sign and symptoms of
BP damage. Post-hoc comparisons were done using Tukey-Kramer method to account for multiple significance testing.
Results: The mean and maximum doses to BP were significantly different (p < .05) based on tumor site, nodal status
and tumor stage. The mean volume to the ipsilateral BP for V50, V60, V70, and V75 were 7.01 cc, 4.37 cc, 1.47 cc and
0.24 cc, respectively. The mean dose delivered to ≤5% of ipsilateral BP was 68.70 Gy (median 69.5Gy). None of the
patients had acute or late brachial plexopathy or any other significant neurological complications, with a minimum
follow up of two years (mean 54 months).
Conclusions: In this study cohort, at a minimum of two-years follow up, the mean dose of 68.7Gy, a median dose to
69.5Gy to ≤5% of ipsilateral BP, and a median Dmax of 72.96Gy did not result in BP injury when patients were treated
with S-IMRT technique. However, longer follow up is needed.
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Radiation therapy may induce brachial plexopathy.
Current Radiation Therapy Oncology Group (RTOG)
guidelines suggest dose constraints ranging from 60-66Gy.
We found that over a minimum follow-up of two years
(mean 54 months) none of our patients developed acute
or late brachial plexopathy with a mean, and median dose
of 68.7Gy, and 69.5Gy delivered to less than 5% of ipsilat-
eral BP and a median maximum point dose of 72.96 Gy to
the ipsilateral BP although longer follow-up is necessary.* Correspondence: bmittal@nmh.org
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Concomitant chemo-radiation (CRT) is the current
standard of care for local-regional advanced head and
neck squamous cell carcinoma (HNSCC). Intensity
Modulated Radiation Therapy (IMRT) is the commonly
utilized radiation therapy technique in this setting, either
using Sequential IMRT (S-IMRT) [1] or Simultaneous
Integrated Boost (SIB-IMRT) techniques [2].
Radiation induced brachial plexopathy is a concerning
adverse event among HNSCC patients; it is defined as
neurologic impairment of a transient or permanent nature
as a sequela to radiation therapy [3]. Symptoms include
paresthesia, pain, weakness, and motor dysfunction affect-
ing the chest, shoulder and upper extremity [4]. The Radi-
ation Therapy Oncology Group (RTOG) has endorsed an
atlas that has been developed and validated for delineatingl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ing BP contouring [5-7]. Limits on the dose to the BP in
patients receiving IMRT have been recommended by the
RTOG to 60–66 Gy on most RTOG clinical protocols
including; RTOG 0435 (≤60 Gy), RTOG 0522 (≤60 Gy),
RTOG 0412 (Dmax 60 Gy), and RTOG 0615 (≤66 Gy).
However, based on tumor location and stage, some pa-
tients may be treated to higher doses of radiation to the
BP. Furthermore, radiation therapy induced brachial
plexopathy may vary depending on dose per fraction, total
dose and volume of BP exposed to radiation and the use
of CRT [3]. Most of the published data regarding dose to
the BP are based on 2D/3D or SIB-IMRT planning tech-
niques. This is the first report evaluating the dose/volume
relationship to radiation-induced brachial plexopathy in pa-
tients with locally advanced HNSCC treated with S-IMRT.
Methods
Patient selection & adverse event reporting
The institutional review board of Northwestern University
approved this study. From January 2003 to December
2008 a total of 68 patients with HNSCC were treated with
S-IMRT. Patients were treated to a prescribed dose of
54–72 Gy with or without concurrent chemotherapy.
Lower doses were prescribed to patients treated in adju-
vant fashion. All patients had a minimum of two years
follow-up. Brachial plexopathy was retrospectively deter-
mined according to the Common Terminology Criteria
for Adverse Events version 3.0.
Immobilization and simulation
Patients were immobilized using an Aquaplast face mask
(WFR/Aquaplast Corp, Wyckoff, New Jersey). Treatment
planning CT scan was performed using IV contrast in
the majority of patients. CT imaging included the region
between the vertex and carina with 3 mm slice
thickness.
Target volumes definition
The details of S-IMRT target volume definition and treat-
ment planning have been reported [1]. The following
guidelines were used:
1. Definitive S-IMRT:
The gross tumor volume (GTV) included clinically and/
or radiologically visible disease. Clinical target volume 1
(CTV1) included GTV and high and low risks elective
nodal regions in the neck with a 1 – 2 cm margin. Clinical
target volume 2 (CTV2) included GTV and high-risk
elective nodal regions with 0.75 – 1.5 cm margin. Clinical
target volume 3 (CTV3) included GTV expanded by 0.5 –
1 cm to cover any microscopic soft tissue extension.Three planning target volumes (PTV 1 – 3) were cre-
ated that encompassed the corresponding CTV with a
margin of 3 – 5 mm to account for set up and patient
movement errors. Later on, for sake of simplicity, we only
outlined GTV and three PTVs that encompassed corre-
sponding CTVs as defined above. We used axial images
from the planning CT to identify nodal levels in the neck
as described by Som et al. [8]. We largely used the histor-
ical data for neck metastases summarized by Chao et al.
[9] to stratify nodal disease as high-risk and low-risk for
elective neck irradiation.
2. Post-operative S-IMRT:
The surgical bed was defined as the area of pre-
operative GTV and the operated area that included the
resected tumor, involved lymph nodes and post-surgical
changes. CTV1 included the surgical bed and regional
high and low risk elective nodal chain with 1–2 cm mar-
gin. CTV2 included surgical bed and high-risk elective
nodal chain with 1 – 2 cm margin. In patients with high-
risk features like extra-capsular extension (ECE) the sur-
rounding soft tissue was included with a generous margin.
Similar to definitive S-IMRT, each CTV was expanded by
3 – 5 mm to create PTV1 and PTV2 and later on for
simplicity, the surgical bed and 2–3 PTVs were created.
In both definitive as well as post-operative cases, the
S-IMRT target volumes were drawn 2 – 3 mm deeper to
the skin to spare dermal structures unless the gross tumor
or ECE was very close to the skin.Dose specifications
Radiation doses were sequentially prescribed using con-
ventional fractionation of 180 – 200 cGy to all patients.
This study included only patients who received once a
day, five-days a week, conventional fractionation and ex-
cluded patients who were treated using hyperfractionated
or accelerated fractionation schemes. Typically, the low
risk target volume (PTV1) was treated to 45 – 50 Gy, the
intermediate to high-risk target volume (PTV2) was
treated to 56 – 66 Gy and the gross tumor with expansion
(PTV3) was treated to 66 – 72 Gy. Three separate IMRT
plans corresponding to each PTV were generated and
whole neck IMRT was used.Dose optimization
Treatment planning utilized 7 – 9 beams inverse planning
IMRT technique. For all target PTVs, maximum dose was
used to restrict dose to <110% of the prescribed dose,
whereas maximum dose-volume histograms (DVH) was
used to restrict the 105% dose volume inside PTV and
minimum DVH used to ascertain that at least 95% of the
PTV is covered by 100% of the prescribed dose.
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DVH, and max Equivalent Uniform Dose were used as
optimization criteria. To achieve a clinically acceptable
plan, the objective values and weights were iteratively
adjusted with the following order of priority: (1) minimize
the maximum dose to the serial organs such as the spinal
cord and brainstem; (2) minimize the mean dose to the
swallowing organs at risk (OARs) such as the pharyngeal
constrictors, larynx, postcricoid esophagus, as well as BP;
and (3) minimize the mean dose to parotids and oral cavity.
Computational method for analysis of dose to BP
For each patient, the Pinnacle Treatment Planning system
was used to generate a text file that contained DVH data,
PTV volumes, and treatment plan statistics. MATLAB
(version 2012a) was then used to format and parse the
data into an Excel workbook for further analysis. The total
prescribed dose was calculated by fraction size and the
number of individual prescriptions by assigning a dose in
cGy to the volumes in the DVH based on the bin size
and number (i.e., bin 1 would be 0 cGy, bin 2 would be
50 cGy, bin 3 would be 100 cGy, etc.). The percent of total
prescribed dose to each total region of interest (ROI)
volume was then calculated. In order to verify that values
calculated by the MATLAB programs were correct, calcu-
lations were replicated in Excel with the raw data. The
calculated values from MATLAB agreed with the Excel-
generated values to within an average of 0.003%.
DVH analysis of BP dose
The volume of BP receiving a specified dose in Grays
(Vds) was computed in cc (i.e. V50 – V75). The dose inFigure 1 Digital reconstructed radiograph of contoured brachial plexus wi
images of representative slices contoured with the right and left BP.Gray covering a specified percent of BP volume (Dvs)
was also tabulated (i.e. D5 – D30). The mean, median
and maximum, V50, V60, V70, V75, D5, D10, D15, D20,
D25, D30 values of ipsilateral and contralateral BP were
calculated based on tumor site and stage.
Brachial plexus contouring technique
The BP was contoured on both sides per the RTOG-
endorsed brachial plexus contouring atlas [5]. The right
and left brachial plexi were contoured with a 3-5-mm
diameter paint tool as separate regions of interest (ROI) in
all patients. The ROIs were delineated by one radiation
oncologist and reviewed and adjusted when considered
appropriate by a second radiation oncologist. Figure 1
shows an example of our BP-contouring technique.
Follow up
Patients were seen in follow-up at 1 month after comple-
tion of radiation, followed by approximately every
3 months in the first year, every 4 months in the 2nd year
and every 6 months for five years then with yearly follow-
ups thereafter. The first imaging study CT and or PET
scan was obtained 1–3 months after treatment to assess
response and thereafter as indicated. Patients usually had
an imaging study performed once a year. Radiation
induced brachial plexopathy was diagnosed if the affected
side was within the prior radiation field and the symptoms
were not due to another known etiology (i.e. tumor
progression or acute injury). All adverse events were
retrospectively reported based on the Common Termin-
ology Criteria for Adverse Events version 3.0 (CTCAE
v3.0). Based on CTCAE v3.0 injury to the BP was gradedth the right BP in magenta and left BP in cyan. Right panel shows axial
Table 1 Patient and tumor characteristics
Characteristics
Age (in years) Mean 56
Median 55
Range 30-89




Sex Male 57 84%
Female 11 16%
Total 68 100%





















Unknown Primary 10 14.7%
Total 68 100%
Aim of treatment Definitive 50 73.5%
Adjuvant + Postop 18 26.5%
Total 68 100%
Chemotherapy Yes 59 86.8%
No 9 13.2%
Total 68 100%
*Nasopharynx Squamous Cell Carcinoma.
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atic not interfering with activities of daily living, grade 3
was symptomatic and interfering with activities of daily
living, grade 4 was disabling and grade 5 was death. As
per our institutional practice, regular follow up for HNSCC
patients included evaluation of treatment-induced adverse
events that were graded according to CTCAE v3.0 and
reported in the patients’ charts.
Statistical analysis
Dose parameters were compared across categories of clin-
ical variables (tumor site, nodal status, stage) using analysis
of variance, accounting for different levels of variation
across categories. Post-hoc comparisons were done using
the Tukey-Kramer method, which accounts for multiple
significance testing [10]. Statistical significance was indicated
when p < 0.05.
Results
Patient and tumor demographics
Table 1 lists patient and tumor characteristics for the
68 patients in the study. Notably, most patients were
male (84%) and most had stage IV disease (76.47%).
Thirty-eight percent of patients had T2 disease and 61.8%
of patients had N2 disease. The oropharynx (48.5%) was
the most commonly treated site. Fifty patients were
treated definitively with the remainder treated adjuvantly
and 86.8% of cases were treated with chemotherapy.
Tumor site, stage and BP dose association
The mean volume of BP was 11.6 cc (Median, 11.6 cc).
Table 2 shows the association between components of the
DVH for both ipsilateral and contralateral BP compared
across categories of clinical variables including tumor
site, nodal status, and tumor group stage. For ipsilateral
BP, comparisons of DVH components across sites were
significant except for volume of BP receiving >70Gy (V70)
or >75Gy (V75). When significant, these components
were lowest for oral cavity and hypopharynx tumors.
Comparisons of ipsilateral DVH components across nodal
status were significant for all components with N0 and N1
tumors having lower values than N2 and N3 nodes. Com-
parisons of ipsilateral tumors by stage of disease were
significant only for V60, D10, and D20 where stage III or
lower stage tumors had lower values than stage IV tumors.
DVH components for the contralateral BP were significant
across sites except for volume of BP receiving >70Gy (V70)
and >75Gy (V75). When significant, oral cavity and oro-
pharyngeal tumors had lower values than other tumors.
Based on nodal status, contralateral DVH components
were significant except for the maximum dose, volume of
BP receiving >70Gy (V70) and >75Gy (V75), and when
significant, showed an increase in values with increasing
nodal stage. However when stage group was evaluated fordose parameters for the contralateral BP only mean dose,
and volume of BP receiving >50Gy were significantly differ-
ent with lower stage tumors having lower values.
Table 2 Association between tumor site, nodal status,
group stage and BP dose
Combined BP
(n = 136)






Mean dose 0.005 0.0002 0.037
Max dose 0.0002 0.002 0.17
V50cc 0.012 < .0001 0.049
V60cc 0.0003 < .0001 0.08
V70cc 0.002 < .0001 0.33
V75cc 0.19 0.08 0.039
D5 0.0005 0.0001 0.12
D10 < .0001 < .0001 0.026
D15 0.0006 < .0001 0.06
D20 0.003 < .0001 0.022
D25 0.22 < .0001 0.10







Mean dose < .0001 < .0001 0.06
Max dose 0.038 0.021 0.20
V50cc 0.004 0.001 0.10
V60cc 0.019 < .0001 0.010
V70cc 0.53 < .0001 0.06
V75cc 0.53 0.001 0.28
D5 0.004 0.0004 0.11
D10 0.003 < .0001 0.007
D15 0.001 0.0006 0.08
D20 0.001 < .0001 0.021
D25 0.013 0.0003 0.14
D30 0.0004 0.0004 0.06
Contralateral
BP (n = 68)






Mean dose < .0001 0.004 0.045
Max dose < .0001 0.10 0.29
V50cc 0.003 0.006 0.041
V60cc < .0001 0.021 0.44
V70cc 0.15 0.20 0.66
V75cc 0.15 0.86 0.52
D5 < .0001 0.042 0.21
D10 < .0001 0.030 0.14
D15 0.0001 0.004 0.09
D20 < .0001 0.009 0.11
D25 < .0001 0.018 0.19
D30 < .0001 0.006 0.13
OC = oral cavity, OPhx = oropharynx, NPhx = nasopharynx, UNP = unknown
primary, HPhx = Hypopharynx.
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For the ipsilateral BP the mean volume receiving more
than 60Gy (V60) was 4.37 cc or 37.74% (median 3.92 cc
or 36%) and 70Gy (V70) was 1.47 cc or 12.74% (median
44 cc or 3.84%). Whereas the mean volume to the
contralateral BP receiving more than 60Gy (V60) was
2.0 cc or 17.9% (median 0.5 cc or 4.56%) and 70Gy
(V70) was 0.43 cc or 3.74% (median 0 cc). Of note the
median V70Gy for the ipsilateral BP was 3.84% of the BP
volume (0.44 cc), implying that at least 50% of the patients
had a <5% of the ipsilateral BP volume receiving ≥ 70 Gy
(Table 3).
Percentage of brachial plexus receiving dose (%)
For ipsilateral BP (n = 68) the mean dose delivered to ≤ 5%
of the BP volume (D5) was 68.7 Gy (median 69.5 Gy,
range 45 – 79.25 Gy), to 10% (D10) was 67.37Gy (median
68.50Gy, range 35.5 – 78 Gy) and to 15% (D15) was
64.98 Gy (median 61Gy, range 10.5 – 77.25 Gy). The
mean and median maximum point doses (Dmax) to the
ipsilateral BP were 71.31 Gy, and 72.96 Gy respectively
(range: 48.99 Gy – 78.17 Gy). The mean, median, and
maximum D5%, 10%, 15%, 20%, 25%, 30%, as well
as Dmax were also calculated for the ipsilateral and
contralateral BP (Table 4). Of note the mean D5% to
the contralateral BP was 59.07Gy (median 60Gy, range
15Gy - 75Gy), and the median Dmax to the contralateral
BP was 62.24 Gy (mean 61.77 Gy, range 18.79 Gy –
76.16 Gy).
Follow up & toxicity
The minimum follow up was 2 years (mean 54 months;
range 24–108 months) for our patient cohort. A substan-
tial percentage of our patients received higher than rec-
ommended doses to BP due to advanced tumor stage or
location without adverse events. Three patients developed
BP symptoms. However no case was due to radiotherapy
or disease progression. One patient acutely developed
grade 2 weakness in the ulnar nerve distribution after
being hospitalized for systemic infection. MRI in this case
revealed diskitis from vertebral levels C7-T1 with evidence
of a phlegmon encompassing the associated nerve roots.
Another patient acutely developed grade 3 right hand
weakness immediately after a traumatic motorcycle injury,
with imaging revealing fracture of vertebral levels C6-C7
and significant soft tissue injury. A third patient developed
grade 1 finger parasthesias with workup imaging revealing
degenerative disk disease with severe cervical spinal sten-
osis as well as neuroformainal stenosis, corresponding to
the affected dermatome.
Discussion
In spite of high dose none of the patients experienced
signs or symptoms of radiation induced BP injury; we are
Table 3 Volume of BP receiving 50 Gy, 60 Gy, 70 Gy, and 75 Gy
Combined BP (n = 136) V50Gy V60Gy V70Gy V75Gy
cc % cc % cc % cc %
Mean 6.27 54.11 3.18 27.82 0.95 8.24 0.13 1.13
Median 6.62 62.60 2.47 23.20 0.00 0.00 0.00 0.00
Maximum 14.93 89.20 12.35 86.00 8.06 75.80 6.61 62.18
Ipsilateral BP (n = 68) V50Gy V60Gy V70Gy V75Gy
cc % cc % cc % cc %
Mean 7.01 60.23 4.37 37.74 1.47 12.74 0.24 2.01
Median 7.46 66.70 3.92 36.00 0.44 3.84 0.00 0.00
Maximum 14.93 89.20 12.35 86.00 8.06 75.80 6.61 62.18
Contralateral BP (n = 68) V50Gy V60Gy V70Gy V75Gy
cc % cc % cc % cc %
Mean 5.53 48.00 2.00 17.90 0.43 3.74 0.03 0.26
Median 5.49 49.10 0.50 4.56 0.00 0.00 0.00 0.00
Maximum 12.06 87.80 11.13 77.60 7.51 54.70 1.20 11.71
The volumes of BP in centimeters cubed (cc) and in percent volume (%) are calculated for the mean, median and maximum doses to the combined, ipsilateral
and contralateral BP.
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isons. In our study, using S-IMRT for HNSCC patients
treated with or without chemotherapy, a mean dose of
68.70Gy and a median dose of 69.50Gy to ≤5% of the
ipsilateral BP volume did not result in any BP injury. The
mean volume of ipsilateral BP receiving a mean dose of
70Gy (V70) was 1.47 cc, 75Gy (V75) was 0.24 cc suggest-
ing that the volume of BP treated to high dose is relatively
small. Even though each axon in the BP functions
as a serial structure, the complex, multiple anastomosing
arrangements of roots, trunks, divisions, and branches
provide a parallel network that could mask and potentially
underrepresent symptoms from a focal lesion, while no
symptomatic events were identified in this study, the possi-
bility of asymptomatic focal injury could not be excluded.Table 4 Percent of brachial plexus receiving given dose in Gr
Combined BP (n = 136) Dmax (Gy) D5% (Gy) D10% (G
Mean 66.54 63.85 62.46
Median 68.73 65.50 63.50
Maximum 78.74 78 77.5
Ipsilateral BP (n = 68) Dmax (Gy) D5% (Gy) D10% (G
Mean 71.31 68.70 67.37
Median 72.96 69.50 68.50
Maximum 78.74 78 77.5
Contralateral BP (n = 68) Dmax (Gy) D5% (Gy) D10% (G
Mean 61.77 59.07 57.78
Median 62.236 60.00 59.75
Maximum 76.16 75.00 74.40
The dose delivered to a specified percent (5% or D5%, 10% or D10%, 15% or D15%
the mean, median and maximum doses to the combined, ipsilateral and contralateIn treatment planning, attention to the BP will con-
tinue to be important to minimize long-term side effects.
Chen et al. [2] reported on subjective symptoms experi-
enced by H & N patients related to brachial plexopathy
using a symptom questionnaire with a median follow-up
of 56 months; in this study 12% of patients reported
positive symptoms. Of note 40% of these patients were
treated with CRT and 62% of these patients were treated
with IMRT using SIB technique where the dose per frac-
tion was as high as 2.12Gy. In our study, with a median
follow up of 49 months, all patients were treated using
S-IMRT with conventional fractionation and a maximum
dose per fraction of 2Gy prescribed to the target volume,
with progressively shrinking field resulting in lower dose
per fraction and reduced BP volume in the radiation fielday (Gy)
y) D15% (Gy) D20% (Gy) D25% (Gy) D30% (Gy)
60.17 59.48 58.23 56.91
61.00 61.80 59.50 58.00
77 76.50 76.00 75.5
y) D15% (Gy) D20% (Gy) D25% (Gy) D30% (Gy)
64.98 63.53 62.52 60.90
66.25 63.50 63.50 62.25
77 76.50 76.00 75.5
y) D15% (Gy) D20% (Gy) D25% (Gy) D30% (Gy)
55.60 55.03 53.87 53.04
57.50 57.00 55.00 54.00
74.00 73.90 73.50 73.00
, 20% or D20%, 25% or D25%, 30% or D30%) of BP in Gy was calculated for
ral BP.
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injury to BP in our patients. The differences in dose per
fraction and spatial distribution of high dose volume be-
tween SIB and S-IMRT technique may have resulted in no
injury to BP in our patients. A smaller study of 43 patients
from Belgium evaluated H & N cancer patients treated
with CRT and found no cases of brachial plexopathy [11].
Radiation therapy in this study was delivered to 35% of pa-
tients using IMRT with the remainder of patients treated
with 3-dimensional conformal radiotherapy. Of note these
patients were treated with 2Gy per fraction daily to 40Gy
followed by 1.6Gy twice a day to a total dose of 72Gy in
6 weeks. This suggests that dose per fraction may also play
an important role in risk of brachial plexopathy.
The use of CRT may increase the risk of brachial
plexopathy although quantifying this risk is difficult. It
has been suggested that a range exists from a two-fold
effect to higher [12,13]. More recently dose constraints
from Amini et al. [14] showed that patients treated for
superior sulcus lung cancers with definitive CRT require
that a median dose to the BP be kept below 69Gy and
the maximum dose to 2 cc below 75Gy to prevent brachial
plexopathy. We found no significant difference in the risk
of brachial plexopathy for patients treated with or without
CRT although most of our patients were treated with CRT.
Over the years dose tolerance as specified from Emami
et al. [15] and more recently Quantec [16] note a 5% risk
of developing radiation-induced brachial plexopathy at
5 years when one-third, two-thirds, and the whole BP,
respectively is treated to 62, 61 and 60 Gy; for a 50% risk
at 5 years, the dose tolerances are 77, 76 and 75 Gy
respectively. Recent data suggests that dose to the BP in
patients undergoing IMRT for head and neck malignan-
cies maybe higher [17]. In our study, with a minimum of
2 years follow-up and mean of 54 months, there were no
events of acute or late brachial plexopathy. It may be ne-
cessary to give high doses to the BP depending on tumor
location; however if lower dose per fraction is given, this
may be help to prevent brachial plexopathy although
longer follow up is necessary. The limitations of this
study include the fact that the evidence of brachial
plexopathy was determined by a retrospective review of
charts. Furthermore, despite the fact that RTOG guide-
lines were used to contour the BP and contours were
checked by a Head and Neck experienced board certified
radiation oncologist, it is extremely difficult to visualize
the BP even on a high resolution CT scan and this
process is susceptible to over and under contouring.
With the evolution of technology, the guidelines for tar-
get volume and normal structure definition continue to
evolve. Velde et al. [18] recently published anatomically
validated contouring guidelines for the BP using cadaver,
CT and MRI imaging. The authors concluded that when
the BP is outlined using their methodology 100% of theBP was included while only 37.75% of the BP was in-
cluded when RTOG guidelines were used. This will have
a significant impact on dose-volume data. However, this
guideline needs further validation by other investigators.
Conclusion
In this study cohort, at a minimum of two years follow
up, the mean dose of 68.7Gy, and a median dose to
69.5Gy to ≤5% of ipsilateral BP did not result in BP injury
when patients were treated with S-IMRT technique.
However, longer follow up is needed.
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